Momentum Biotechnologies (“Momentum”) is a specialized CRO focused on providing mass spectrometry-based native detection technologies for lead discovery and the quantification of difficult targets to biopharmaceutical clients globally.

We are the leading provider of solution phase Affinity Selection Mass Spectrometry (ASMS) for RNA and protein targets. We help clients identify leads for novel mechanisms of action such as protein degradation/molecular glues, protein-protein interaction disruption (ASMS), and irreversible binding (Covalent Screening). We offer functional screens on RapidFire-MS, potency assays, and biomarker quantification and can additionally support Cell and Gene Therapy applications through ICP-MS analysis.

We have a large high throughput screening lab and a fully functional BL2 lab in Billerica, Massachusetts.